Filing Flows

Filing Flows › 8-K events › Drugs Made In America Acquisition

Drugs Made In America Acquisition: entry into a material definitive agreement

Form 8-K filed Oct 21, 2026 · items 1.01, 8.01

What the filing says

On October 13, 2026, Drugs Made In America Acquisition Corp. (the “ Company ”) and Power Analytics Global Corp, a Delaware corporation (“ PAGC ”), entered into Amendment No. 1 (the “ Amendment ”) to their Amended and Restated Definitive Merger Agreement dated as of September 8, 2026 (the “ Merger Agreement ”). The Amen

Read the filing on SEC EDGAR →

What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 8.01: +0.1% next session across 44,881. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

Other recent mergers and acquisitions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.